Endometrial cancer

Cell and Tissue Research

Volumn 322, Issue 1, 2005, Pages 53-61

  Ryan, Andrew J ^a   Susil, Beatrice ^a   Jobling, Thomas W ^a   Oehler, Martin K ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Endometrial cancer; Human; Microsatellite instability; Oncogenes; Progression model; Tumour suppressor genes

Indexed keywords

ANGIOGENIC FACTOR; BETA CATENIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; STEROID RECEPTOR;

CANCER CLASSIFICATION; CANCER GENETICS; CARCINOGENESIS; ENDOMETRIUM CARCINOMA; HISTOPATHOLOGY; HUMAN; MISMATCH REPAIR; MOLECULAR BIOLOGY; ONCOGENE; ONCOGENE K RAS; ONCOGENE NEU; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

BASE PAIR MISMATCH; BETA CATENIN; DISEASE PROGRESSION; DNA REPAIR; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PTEN PHOSPHOHYDROLASE; RECEPTORS, STEROID; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27944441775     PISSN: 0302766X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00441-005-1109-5     Document Type: Review

References (72)

1. Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F (1995) Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 86:479-485
2. Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL (2001) Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61:4576-4582
3. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10-17
4. Breivik J, Gaudernack G (1999) Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. Semin Cancer Biol 9:245-254
5. Bryant W, Snowhite AE, Rice LW, Shupnik MA (2004) The estrogen receptor-{alpha} (ER{alpha}) variant {Delta}5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells. Endocrinology 146:751-759
6. Bullions LC, Levine AJ (1998) The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol 10:81-87
7. Catasus L, Matias-Guiu X, Machin P, Zannoni GF, Scambia G, Benedetti-Panici P, Prat J (2000) Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability. Cancer 88:2290-2297
8. Critchley HO, Henderson TA, Kelly RW, Scobie GS, Evans LR, Groome NP, Saunders PT (2002) Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle. J Clin Endocrinol Metab 87:5265-5273
9. De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, Hunter DJ (2002) A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA 99:12263-12268
10. Doldi N, Bassan M, Gulisano M, Broccoli V, Boncinelli E, Ferrari A (1996) Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer. Gynecol Endocrinol 10:375-382
11. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI (1994) The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109-2123
12. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105-110
13. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, Rice JM (1991) K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 51:5308-5314
14. Erkanli S, Eren F, Pekin S, Bagis T (2004) BCL-2 and P53 expression in endometrial carcinoma. J Exp Clin Cancer Res 23:97-103
15. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S (1998) Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 58:3526-3528
16. Geisler JP, Geisler HE, Manahan KJ, Miller GA, Wiemann MC, Zhou Z, Crabtree W (2004) Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and relationship to survival. Int J Gynecol Cancer 14:133-137
17. Giatromanolaki A, Sivridis E, Koukourakis MI, Harris AL, Gatter KC (1998) Bcl-2 and p53 expression in stage I endometrial carcinoma. Anticancer Res 18:3689-3693
18. Gurin CC, Federici MG, Kang L, Boyd J (1999) Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 59:462-466
19. Herynk MH, Fuqua SA (2004) Estrogen receptor mutations in human disease. Endocr Rev 25:869-898
20. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T (2001) Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 80:181-188
21. Holland CM, Day K, Evans A, Smith SK (2003) Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 89:891-898
22. Horikawa I, Barrett JC (2003) Transcriptional regulation of the telomerase hTERT gene as a target cellular and viral oncogenic mechanisms. Carcinogenesis 24:1167-1176
23. Horvath G, Leser G, Hahlin M, Henriksson M (2000) Exon deletions and variants of human estrogen receptor mRNA in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer 10:128-136
24. Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW (2001) Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed Mullerian tumors have altered ER and PR isoform expression. Oncogene 20:6965-6969
25. Kirschner CV, Alanis-Amezcua JM, Martin VG, Luna N, Morgan E, Yang JJ, Yordan EL (1996) Angiogenesis factor in endometrial carcinoma: a new prognostic indicator? Am J Obstet Gynecol 174:1879-188 (discussion 1882-1884)
26. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW (2000) Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Path 13:379-388
27. Lagarda H, Catasus L, Arguelles R, Matias-Guiu X, Prat J (2001) K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 193:193-199
28. Latta E, Chapman WB (2002) PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 14:59-65
29. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88:814-824
30. Lecce G, Meduri G, Ancelin M, Bergeron C, Perrot-Applanat M (2001) Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J Clin Endocrinol Metab 86:1379-1386
31. Levine RL, Cargile CB, Blazes MS, Rees B van, Kurman RJ, Ellenson LH (1998) PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 58:3254-3258
32. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947
33. Machin P, Catasus L, Pons C, Munoz J, Matias-Guiu X, Prat J (2002) CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Human Pathol 33:206-212
34. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, Berchuck A, Futreal PA (1998) Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 58:2500-2503
35. Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D, Holowaty E, Bapat B, Gallinger S, Redston M (1999) Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59:3346-3351
36. Moll UM, Chalas E, Auguste M, Meaney D, Chumas J (1996) Uterine papillary serous carcinoma evolves via a p53-driven pathway. Human Pathol 27:1295-1300
37. Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Garcia-Rostan G, Prat J, Guo M, Herman JG, Matias-Guiu X, Esteller M, Palacios J (2002) Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 21:7981-7990
38. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92:924-930
39. Niederacher D, An HX, Cho YJ, Hantschmann P, Bender HG, Beckmann MW (1999) Mutations and amplification of oncogenes in endometrial cancer. Oncology 56:59-65
40. Oehler MK, Rees MC, Bicknell R (2000) Steroids and the endometrium. Curr Med Chem 7:543-560
41. Oehler MK, Hague S, Rees MC, Bicknell R (2002) Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 21:2815-2821
42. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505-3512
43. Parc YR, Halling KC, Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN, Halling AC (2000) Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: associations with family history and histopathology. Int J Cancer 86:60-66
44. Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X (1994) Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 74:1778-1783
45. Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57:4736-4738
46. Risinger JI, Maxwell GL, Berchuck A, Barrett JC (2003) Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers. Ann N Y Acad Sci 983:208-212
47. Saegusa M, Okayasu I (2000) Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium. Jpn J Cancer Res 91:510-518
48. Saegusa M, Hashimura M, Yoshida T, Okayasu I (2001) Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 84:209-217
49. Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF (1995) Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 55:5693-5698
50. Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62:4849-4853
51. Salvesen HB, MacDonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA, Das S (2000) Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 6:3607-3613
52. Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, Macdonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S (2004) Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol 25:1615-1623
53. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP (2002) Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8:1271-1279
54. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, Kohler MF, Berchuck A, et al (1993) Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 53:1906-1910
55. Sasaki M, Kotcherguina L, Dharia A, Fujimoto S, Dahiya R (2001) Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res 61:3262-3266
56. Schlosshauer PW, Ellenson LH, Soslow RA (2002) Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Path 15:1032-1037
57. Scholten AN, Creutzberg CL, Broek LJ van den, Noordijk EM, Smit VT (2003) Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. J Pathol 201:460-465
58. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI (2002) Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055-1063
59. Skrzypczak M, Bieche I, Szymczak S, Tozlu S, Lewandowski S, Girault I, Radwanska K, Szczylik C, Jakowicki JA, Lidereau R, Kaczmarek L (2004) Evaluation of mRNA expression of estrogen receptor beta and its isoforms in human normal and neoplastic endometrium. Int J Cancer 110:783-787
60. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH (2004) Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22:3126-3132
61. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362
62. Takai N, Ueda T, Nishida M, Nasu K, Miyakawa I (2004) The relationship between oncogene expression and clinical outcome in endometrial carcinoma. Curr Cancer Drug Targets 4:511-520
63. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L (1997a) p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150:177-185
64. Tashiro H, Lax SF, Gaudin PB, Isacson C, Cho KR, Hedrick L (1997b) Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 150:75-79
65. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532
66. Wang Z, Kyo S, Maida Y, Takakura M, Tanaka M, Yatabe N, Kanaya T, Nakamura M, Koike K, Hisamoto K, Ohmichi M, Inoue M (2002) Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene 21:3517-3524
67. Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT (1994) The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 96:516-520
68. Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M, Gustafsson JA (2000) Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci USA 97:5936-5941
69. Williams JA Jr, Wang ZR, Parrish RS, Hazlett LJ, Smith ST, Young SR (1999) Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer. Exp Mol Pathol 67:135-143
70. Yin Y, Solomon G, Deng C, Barrett JC (1999) Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress. Mol Carcinog 24:15-24
71. Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Sakamoto A, Sakamoto T, Maruyama H, Sato S, Mizunuma H, Smith SK (2003) Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 9:1361-1369
72. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA (1996) p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 61:167-174